Welcome to our dedicated page for BBI news (Ticker: BBI), a resource for investors and traders seeking the latest updates and insights on BBI stock.
Brickell Biotech, Inc. (BBI) is a clinical-stage pharmaceutical company dedicated to developing innovative and differentiated prescription therapeutics for debilitating skin diseases. With a primary focus on its lead asset, sofpironium bromide, Brickell is targeting the treatment of hyperhidrosis, a condition characterized by excessive sweating.
Brickell's executive management team and board of directors are seasoned professionals with significant experience in product development and global commercialization. They have previously held leadership roles at major pharmaceutical companies, contributing to the development and launch of successful products such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, and Juvederm®.
Brickell's strategic approach involves leveraging its team's vast experience to in-license, acquire, develop, and commercialize distinctive pharmaceutical products. The company aims to address unmet patient needs and bring transformative solutions to the market.
Recent updates indicate that Brickell is strengthening its cash position while exploring strategic options to maximize shareholder value. Additionally, the company plans to make cash distributions to shareholders, estimated to range between $5 million and $7 million, or $0.84 to $1.17 per share, pending shareholder approval and the filing of the certificate of dissolution.
Brickell Biotech, Inc. (Nasdaq: BBI) has initiated the Phase 1 clinical trial for its oral DYRK1A inhibitor, BBI-02, targeting autoimmune and inflammatory diseases. The trial comprises a single ascending dose (SAD) part, which has already begun dosing subjects. The study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of BBI-02. Topline results from both SAD and the subsequent multiple ascending dose (MAD) segments are anticipated by early 2023. BBI-02 shows promise in preclinical models, potentially offering a better therapeutic approach than existing agents.
Brickell Biotech completed the sale of sofpironium bromide to Botanix Pharmaceuticals for an upfront payment of $3 million and up to $6 million in regulatory milestone payments, totaling $168 million in potential future payments. This move aligns with Brickell's new strategy focused on advancing its pipeline of treatments for autoimmune and inflammatory diseases. The company plans to initiate a Phase 1 trial for BBI-02, a potential first-in-class DYRK1A inhibitor, in Q2 2022, with topline results expected by early 2023. Brickell reported Q1 2022 revenue of $92,000 and a net loss of $9.4 million.
Brickell Biotech, Inc. (Nasdaq: BBI) has announced it will report its first quarter financial results on May 12, 2022, at 4:30 p.m. EDT, followed by a conference call and webcast. The company focuses on developing innovative therapeutics for autoimmune and inflammatory diseases, with products like BBI-02 and BBI-10 in its pipeline. BBI-02 is a Phase 1-ready oral DYRK1A inhibitor, while BBI-10 is a novel oral STING inhibitor in preclinical stages. This strategic focus aims to benefit patients with chronic, debilitating diseases.
Brickell Biotech, Inc. (NASDAQ: BBI) has adjourned its 2022 Annual Meeting of stockholders to May 17, 2022, at 10 a.m. MT. Stockholders of record as of March 7, 2022, are urged to vote by May 16, 2022. Although a quorum was met with approximately 51% of common stock represented, key proposals, including an amendment to increase authorized shares and a reverse stock split, lacked sufficient votes for approval. Stockholders who have not voted are encouraged to participate, while proxies submitted prior will remain effective for the adjourned meeting.
Brickell Biotech (Nasdaq: BBI) has finalized a deal with Botanix SB Inc. involving the sale of rights to sofpironium bromide, a topical therapy for hyperhidrosis. The agreement includes $9 million in upfront payments, potential future milestone payments totaling $168 million, and tiered earn-out payments on net sales. This strategic move signifies Brickell's shift towards immunology and inflammation therapies, as they plan to invest proceeds into their pipeline, including advancing their lead candidates BBI-02 and BBI-10.
Brickell Biotech (BBI) announced its strategic focus on immunology and inflammation with the acquisition of BBI-02, a first-in-class DYRK1A inhibitor, alongside novel STING inhibitors. The company is set to initiate a Phase 1 study for BBI-02 in Q2 2022, expecting topline results by year's end. Additionally, a New Drug Application for sofpironium bromide gel, 15% is planned for mid-2022. Financials show a net loss of $39.5 million for 2021, while revenue dropped to $0.4 million from $1.8 million the previous year, largely due to decreased collaboration revenue.
Brickell Biotech, Inc. (Nasdaq: BBI) announced that the results from its US Phase 3 pivotal studies, Cardigan I and Cardigan II, on sofpironium bromide gel (15%) for treating primary axillary hyperhidrosis will be presented at the AAD's Annual Meeting on March 26, 2022, in Boston, MA. This presentation will cover the efficacy of the gel in reducing excessive sweating. Brickell continues to focus on developing innovative therapeutics for autoimmune and inflammatory diseases, leveraging a strong pipeline and experienced management team.
Brickell Biotech, Inc. (Nasdaq: BBI) will report its fourth quarter and full year 2021 financial results on March 15, 2022. The management will host a conference call at 8:30 a.m. EDT to discuss these results and recent corporate highlights. Interested parties can access the call via a dedicated phone line or by webcast on Brickell's investor website. The company focuses on developing innovative therapeutics for autoimmune and inflammatory diseases, highlighting a diverse pipeline including a promising late-stage program for primary axillary hyperhidrosis.
Brickell Biotech (Nasdaq: BBI) announces a licensing agreement with Carna Biosciences to acquire worldwide rights to develop and commercialize next-generation STING inhibitors. This strategic partnership aims to enhance Brickell's pipeline in immunology and inflammatory diseases. The lead candidate, BBI-10, shows promise in reducing cytokines, with a payment structure involving an upfront fee of $2 million and potential milestone payments totaling $258 million. Brickell anticipates advancements in its immunology portfolio as it prepares for clinical trials.
Brickell Biotech announced positive topline results from two Phase 3 studies of sofpironium bromide gel for primary axillary hyperhidrosis, achieving statistical significance in all endpoints. The company plans to submit a New Drug Application (NDA) to the FDA in mid-2022. Brickell also aims to initiate a Phase 1 study for its lead DYRK1A inhibitor, BBI-02, expected in the first half of 2022. Financially, the company reported a net loss of $13.3 million in Q3 2021 and raised $8.9 million from an equity offering to strengthen its balance sheet.
FAQ
What is the market cap of BBI (BBI)?
What does Brickell Biotech, Inc. specialize in?
What is Brickell Biotech, Inc.'s lead asset?
Who are the key members of Brickell Biotech's leadership team?
What is the company's strategy for growth?
Has Brickell Biotech recently made any significant financial moves?
What are the planned cash distributions to shareholders?
What notable products have Brickell's leadership previously worked on?
What are Brickell Biotech's recent achievements?
What are the focus areas for Brickell's R&D efforts?
How does Brickell Biotech plan to transform patient care?
